In considering mitochondrial diseases, it is helpful to put the subject into some evolutionary perspective. Mitochondria owe their existence, it is hypothesized, due to the ancient fusion of bacteria and protocells. Bacterial DNA eventually became mitochondrial DNA (mtDNA) and throughout subsequent evolution the cell's nuclear DNA (nDNA) and mtDNA have developed a separate and symbiotic relationship. Despite billions of years of evolutionary coexistence, the genetic codes for mtDNA and nDNA remain different. Human mtDNA (16,569 base pairs) has no noncoding intron DNA sequences, as distinct from nDNA (3 x 109 base pairs), which is composed mainly of noncoding segments, including introns. The spontaneous, natural mutation rate for mtDNA is proposed to be 10 times that for nDNA. As mtDNA lacks noncoding introns, most mutations should involve regulatory or coding sequences, even though many such mutations do not overtly alter the mitochondrion's function. It is said that these are neutral mutations, and natural selection may not eliminate them.1,2 Mitochondrial DNA mutations are silent when they do not change the encoded amino acid and missense when the encoded amino acid is changed. Transition mutations (mutations of a pyrimidine base to another pyrimidine or a purine base to another purine) are known to occur more frequently than transversions (mutation of a purine base to a pyrimidine or vice versa). This theme is pertinent to the described human mtDNA mutations in which the mutations remain of the transition type.3 3
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Hirano and Pavlakis4 in their fine review published in this issue of the Journal of Child Neurology have given us the essential facts about the syndrome of mitochondrial encephalopathy, lactic acidosis, and strokelike episodes (MELAS). They describe the clinical spectrum in 110 reported mitochondrial encephalopathy, lactic acidosis, and strokelike episodes patients. Incredible progress in understanding the molecular basis of mtDNA disease has occurred in the brief time since Holt et al5 described deletions of mtDNA in patients with mitochondrial myopathies and the mutations described in a mito-chondrial tRNALys in myoclonus epilepsy and ragged-red fiber disease (MERRF)6,7 and in mitochondrial tRNALe°a nd in the ND4 subunit of the respiratory complex 1 for mitochondrial encephalopathy, lactic acidosis, and strokelike episodes patients.8--10 Hirano and Pavlakis4 found six cardinal manifestations in 90% of mitochondrial encephalopathy, lactic acidosis, and strokelike episodes patients: clinical stroke, seizures, lactic acidosis, ragged-red fibers, exercise intolerance, and onset of symptoms before age 40 years.
Dementia, normal early development, and limb weakness were also quite common features. At least three genotypes have been described corresponding to these mitochondrial encephalopathy, lactic acidosis, and strokelike episodes patients: two different tRNALeu(UUR) mutations and one in subunit 4 of complex 1 (ND4). A purine-topurine mutation (A-to-G) transition at nucleotide 3243 of tRNALeu(UUR) (MELAS-3243) is found in 80% to 90% of patients. A pyrimidine-to-pyrimidine transition mutation (T-to-C) of tRNALeu(UUR) at 3271 (MELAS-3271) has been found in only three patients and only one with the ND4 mutation. The interesting feature is a stereotyped clinical phenotype due to three different genotypes with a strong emphasis involving TRNA Leu(uuR) The other way around, Moraes et alll evaluated persons with the 3243 mutation who did not conform to the classic mitochondrial encephalopathy, lactic acidosis, and strokelike episodes syndrome. Twenty-one patients with the 3243 mutation were studied, and 15 had the progressive external ophthalmoplegia syndrome and one had the Kearns-Sayre syndrome. A third clinical phenotype with the MELAS 3243 mutation had maternally inherited diabetes mellitus and deafness.
Thus, not all mitochondrial encephalopathy, lactic acidosis, and strokelike episodes patients had the 3243 mutation and not all 3243 mutations corresponded with the mitochondrial encephalopathy, lactic acidosis, and strokelike episodes syndrome. Three genotypes producing the mitochondrial encephalopathy, lactic acidosis, and strokelike episodes syndrome is interesting, but the variation in expression of the clinical phenotype due to the same 3243 mutation is even more interesting.
The observations of King et al 12 are of great interest to this discussion of clinical variation in the 3243 mutation and raise more questions than they answer. Cytoplasts (cells devoid of nuclei) from two unrelated patients with mitochondrial encephalopathy, lactic acidosis, and strokelike episodes with the A-to-G transition mutation at nucleotide 3243 in the mitochondrial tRNALeu(UUR) gene were fused with human cells lacking endogenous mtDNA (p° cells). Cybrids containing at least 95% mutant mtDNA but not those cells containing normal mtDNA, exhibited decreases in the rates of synthesis and in the steady-state levels of the mitochondrial protein translation products. They also found that reduced nicotinamide adenine dinucleotide dehydrogenase subunit 1 (ND1) exhibited a slightly altered mobility on polyacrylamide gel electrophoresis. The 3243 mutation also resulted in a severe respiratory chain deficiency. The cybrid-3243 mutation mtDNA fused cells resulted in a consistent biochemical defect in vitro. What then are the other complex issues to explain the clinical variation encountered in patients with the 3243 mutation? In the final analysis, the clinical variation should correlate with the degree of heteroplasmy (ratio of mutant to normal mitochondria) in specific anatomic neuronal and glial populations affecting necessary threshold levels of adenosine triphosphate (ATP) production. One distribution of mutant 3243 mtDNA produces the mitochondrial encephalopathy, lactic acidosis, and strokelike episodes syndrome, another Keams-Sayre syndrome, and another diabetes and deafness. These differing patterns of heteroplasmy in different brain regions may be in large part due to mtDNA and nDNA polymorphisms, driven by evolutionary time and also underdeveloped mtDNA repair mechanisms allowing mtDNA mutations to accumulate,13 and to the complementary integrated biochemical functions between the two genomes. Hirano and Pavlakis4 do consider this possibility by stating: &dquo;Perhaps nDNA-encoded factors or synergistic mtDNA polymorphisms can affect the phenotypic expression of this mtDNA mutation.&dquo; In my view, they have so expressed great insight and the orientation of future molecular studies.
The late A.C. Wilson and his colleagues have put forward the view that the degree of mutations in mtDNA occurred 10 times faster than in nDNA. Gunther Stent in reviewing Wilson's contributions in a recent eulogy said: &dquo;The molecular clock ticks about 10 times faster in mtDNA than in nDNA, making it possible to ascertain much more recent dates of divergence of the (maternal) ancestors of proband individuals by analysis of the mitochondrial rather than their nuclear DNA.&dquo;14 Our molecular analyses of mtDNA and nDNA from control subjects and patients with mitochondrial encephalopathy, lactic acidosis, and strokelike episodes must take into consideration Wilson's observations of mtDNA divergence and its relationship to specific ethnic and geographic groups. Hirano and Pavlakis4 are correct in seeking answers to clinical-molecular variations in the mtDNA human diseases by pointing us in the direction of mtDNA and nDNA polymorphisms.
Aging may be the ultimate mtDNA disease, as respiratory rate falls in all persons with age, and different rates of decline in mitochondrial respiratory function among individuals may be a crucial determinant of lifespain. 15 The late onset of mtDNA human disease is a function of the loss of respiratory activity with age. The decline in mitochondrial respiratory activity with age allows mutant mtDNA populations to reach a critical threshold and express clinical disease. The mtDNA diseases, aging, mtDNA and nDNA polymorphisms, and human brain evolution may all represent a common set of research objectives approached in slightly different ways. It will be interesting to see if this view is substantiated by future investigation.
